[HTML][HTML] Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari, P Cordelier… - European journal of …, 2016 - Elsevier
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari… - … journal of cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari, P Cordelier… - European Journal of …, 2016 - hal.science
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari… - … Journal of Cancer, 2016 - univ-rennes.hal.science
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
B Bournet, C Buscail, F Muscari… - European Journal of …, 2015 - europepmc.org
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari, P Cordelier… - European Journal of …, 2016 - infona.pl
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari, P Cordelier… - European Journal of …, 2016 - ejcancer.com
Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …
[引用][C] Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
B Bournet, C Buscail, F Muscari, P Cordelier… - European Journal of …, 2016 - cir.nii.ac.jp
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and
realities | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
realities | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …